STAA
STAAR Surgical Company [STAA] Stock Forecast
Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
RSI : 000
STAA Stock Summary
Top 10 Correlated ETFs
STAA
Top 10 Correlated Stocks
STAA
In the News
STAA Financial details
Company Rating
Strong Buy
Market Cap
2.43B
Income
21.35M
Revenue
322.42M
Book val./share
7.91
Cash/share
4.52
Dividend
-
Dividend %
-
Employees
1.06K
Optionable
No
Shortable
Yes
Earnings
01 May 2024
P/E
83.93
Forward P/E
-
PEG
-18.11
P/S
5.35
P/B
4.37
P/C
10.21
P/FCF
-49.5
Quick Ratio
5.29
Current Ratio
6.11
Debt / Equity
0.09
LT Debt / Equity
0.08
-
-
EPS (TTM)
0.45
EPS next Y
-
EPS next Q
-
EPS this Y
-46.99%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
6.58%
Revenue last 5Y
16.51%
Revenue Q/Q
-5.02%
EPS Q/Q
61.45%
-
-
-
-
SMA20
26.32%
SMA50
65.52%
SMA100
41.18%
Inst Own
97.06%
Inst Trans
0.93%
ROA
4%
ROE
6%
ROC
0.04%
Gross Margin
78%
Oper. Margin
6%
Profit Margin
6%
Payout
-
Shs Outstand
-
Shs Float
-
-
-
-
-
Target Price
-
52W Range
26.66-73.13
52W High
-36.77%
52W Low
+77.54%
RSI
60
Rel Volume
0.34
Avg Volume
736.24K
Volume
246.74K
Perf Week
-10.54%
Perf Month
28.72%
Perf Quarter
19.74%
Perf Half Y
5.44%
-
-
-
-
Beta
0.877
-
-
Volatility
1.18%, 5.24%
Prev Close
-1.3%
Price
46.16
Change
-0.88%
STAA Financial Performance
Yearly Fundamentals Overview
Last date of statement is 2023-12-29
| Metric | History | 2020-01-03 | 2021-01-01 | 2021-12-31 | 2022-12-30 | 2023-12-29 |
|---|---|---|---|---|---|---|
| 2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
| Revenue per share | 3.38 | 3.58 | 4.88 | 5.93 | 6.64 | |
| Net income per share | 0.32 | 0.13 | 0.58 | 0.83 | 0.44 | |
| Operating cash flow per share | 0.58 | 0.46 | 0.93 | 0.74 | 0.3 | |
| Free cash flow per share | 0.35 | 0.28 | 0.64 | 0.37 | -0.07 | |
| Cash per share | 2.7 | 3.34 | 4.23 | 4.41 | 4.55 | |
| Book value per share | 3.59 | 4.32 | 5.48 | 6.93 | 7.95 | |
| Tangible book value per share | 3.55 | 4.28 | 5.43 | 6.89 | 7.92 | |
| Share holders equity per share | 3.59 | 4.32 | 5.48 | 6.93 | 7.95 | |
| Interest debt per share | 0.21 | 0.24 | 0.68 | 0.7 | 0.74 | |
| Market cap | 1.53B | 3.61B | 4.31B | 2.33B | 1.51B | |
| Enterprise value | 1.42B | 3.47B | 4.14B | 2.27B | 1.37B | |
| P/E ratio | 108.89 | 611 | 156.67 | 58.72 | 70.94 | |
| Price to sales ratio | 10.19 | 22.1 | 18.7 | 8.19 | 4.7 | |
| POCF ratio | 59.3 | 172.44 | 98.05 | 65.22 | 103.77 | |
| PFCF ratio | 97.95 | 287.94 | 142.17 | 132.29 | -421.37 | |
| P/B Ratio | 9.57 | 18.32 | 16.67 | 7.01 | 3.92 | |
| PTB ratio | 9.57 | 18.32 | 16.67 | 7.01 | 3.92 | |
| EV to sales | 9.45 | 21.24 | 17.97 | 8 | 4.24 | |
| Enterprise value over EBITDA | 88.33 | 385.69 | 103.71 | 45.46 | 41.15 | |
| EV to operating cash flow | 55.02 | 165.68 | 94.23 | 63.67 | 93.68 | |
| EV to free cash flow | 90.88 | 276.65 | 136.64 | 129.14 | -380.41 | |
| Earnings yield | 0.01 | 0 | 0.01 | 0.02 | 0.01 | |
| Free cash flow yield | 0.01 | 0 | 0.01 | 0.01 | 0 | |
| Debt to equity | 0.06 | 0.05 | 0.12 | 0.09 | 0.09 | |
| Debt to assets | 0.05 | 0.04 | 0.09 | 0.07 | 0.07 | |
| Net debt to EBITDA | -6.87 | -15.74 | -4.2 | -1.11 | -4.43 | |
| Current ratio | 5.07 | 5.25 | 5.56 | 6.03 | 5.62 | |
| Interest coverage | 0 | 0 | -877.34K | 17.89 | 0 | |
| Income quality | 1.84 | 3.54 | 1.79 | 0.92 | 0.68 | |
| Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
| Payout ratio | 0 | 0 | 0 | 0 | 0 | |
| Sales general and administrative to revenue | 0.2 | 0.21 | 0.19 | 0.19 | 0.22 | |
| Research and developement to revenue | 0.17 | 0.2 | 0.15 | 0.13 | 0.14 | |
| Intangibles to total assets | 0.01 | 0.01 | 0.01 | 0 | 0 | |
| Capex to operating cash flow | -0.39 | -0.4 | -0.31 | -0.51 | -1.25 | |
| Capex to revenue | -0.07 | -0.05 | -0.06 | -0.06 | -0.06 | |
| Capex to depreciation | -2.75 | -2.72 | -3.75 | -4.02 | -3.55 | |
| Stock based compensation to revenue | 0.07 | 0.07 | 0.06 | 0.07 | 0.07 | |
| Graham number | 5.05 | 3.55 | 8.47 | 11.35 | 8.87 | |
| ROIC | 0.07 | 0.02 | 0.08 | 0.09 | 0.04 | |
| Return on tangible assets | 0.07 | 0.02 | 0.08 | 0.1 | 0.04 | |
| Graham Net | 2.36 | 2.8 | 3.26 | 3.91 | 4.31 | |
| Working capital | 140.19M | 175.18M | 222.61M | 260.26M | 300.23M | |
| Tangible asset value | 157.8M | 195.17M | 256.55M | 330.48M | 384.17M | |
| Net current asset value | 127.69M | 156.22M | 184.19M | 229.27M | 262.53M | |
| Invested capital | 0.06 | 0.05 | 0.12 | 0.09 | 0.09 | |
| Average receivables | 28.47M | 33.11M | 39.38M | 52.99M | 80.21M | |
| Average payables | 7.29M | 7.96M | 8.29M | 10.14M | 12.57M | |
| Average inventory | 16.92M | 17.63M | 17.69M | 20.72M | 29.65M | |
| Days sales outstanding | 75.33 | 78.67 | 68.94 | 80.15 | 110.92 | |
| Days payables outstanding | 76.86 | 63.73 | 61.25 | 69.26 | 70.93 | |
| Days of inventory on hand | 163.66 | 146.58 | 121.64 | 144.55 | 183.8 | |
| Receivables turnover | 4.85 | 4.64 | 5.29 | 4.55 | 3.29 | |
| Payables turnover | 4.75 | 5.73 | 5.96 | 5.27 | 5.15 | |
| Inventory turnover | 2.23 | 2.49 | 3 | 2.53 | 1.99 | |
| ROE | 0.09 | 0.03 | 0.11 | 0.12 | 0.06 | |
| Capex per share | -0.23 | -0.18 | -0.29 | -0.38 | -0.37 |
Quarterly Fundamentals Overview
Last date of statement is 2023-12-29 for Q4
| Metric | History | 2022-12-30 | 2023-03-31 | 2023-06-30 | 2023-09-29 | 2023-12-29 |
|---|---|---|---|---|---|---|
| 2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
| Revenue per share | 1.33 | 1.52 | 1.91 | 1.65 | 1.56 | |
| Net income per share | 0.12 | 0.06 | 0.13 | 0.1 | 0.16 | |
| Operating cash flow per share | 0.06 | -0.11 | -0.13 | -0.12 | 0.65 | |
| Free cash flow per share | -0.02 | -0.17 | -0.19 | -0.31 | 0.59 | |
| Cash per share | 4.39 | 4.23 | 3.97 | 3.87 | 4.52 | |
| Book value per share | 6.9 | 7.02 | 7.31 | 7.79 | 7.91 | |
| Tangible book value per share | 6.86 | 6.98 | 7.27 | 7.75 | 7.91 | |
| Share holders equity per share | 6.9 | 7.02 | 7.31 | 7.79 | 7.91 | |
| Interest debt per share | 0.68 | 0.7 | 0.67 | 0.74 | 0.7 | |
| Market cap | 2.34B | 3.09B | 2.55B | 1.95B | 1.52B | |
| Enterprise value | 2.28B | 3.03B | 2.48B | 1.86B | 1.38B | |
| P/E ratio | 99.94 | 284.63 | 104.94 | 101.37 | 49.11 | |
| Price to sales ratio | 36.53 | 41.96 | 27.57 | 24.32 | 19.97 | |
| POCF ratio | 787.8 | -605.69 | -403.64 | -326.91 | 47.66 | |
| PFCF ratio | -2.22K | -385.92 | -273.1 | -128.84 | 52.75 | |
| P/B Ratio | 7.04 | 9.1 | 7.2 | 5.16 | 3.95 | |
| PTB ratio | 7.04 | 9.1 | 7.2 | 5.16 | 3.95 | |
| EV to sales | 35.67 | 41.17 | 26.9 | 23.18 | 18.04 | |
| Enterprise value over EBITDA | -2.7K | 779.04 | 208.04 | 206.35 | 116.92 | |
| EV to operating cash flow | 769.14 | -594.29 | -393.77 | -311.59 | 43.05 | |
| EV to free cash flow | -2.17K | -378.65 | -266.43 | -122.81 | 47.65 | |
| Earnings yield | 0 | 0 | 0 | 0 | 0.01 | |
| Free cash flow yield | 0 | 0 | 0 | -0.01 | 0.02 | |
| Debt to equity | 0.09 | 0.09 | 0.09 | 0.09 | 0.09 | |
| Debt to assets | 0.07 | 0.08 | 0.07 | 0.08 | 0.07 | |
| Net debt to EBITDA | 65.46 | -14.94 | -5.21 | -10.15 | -12.51 | |
| Current ratio | 6.03 | 6.65 | 6.05 | 6.11 | 5.62 | |
| Interest coverage | 0.64 | 1.54 | 0 | 0 | -5.71 | |
| Income quality | 0.49 | -1.88 | -1.04 | -1.24 | 4.12 | |
| Dividend Yield | 0 | 0 | 0 | 0 | 0.01 | |
| Payout ratio | 0 | 0 | 0.24 | 1.51 | 1.13 | |
| Sales general and administrative to revenue | 0.23 | 0.25 | 0.2 | 0.24 | 0.22 | |
| Research and developement to revenue | 0.15 | 0.14 | 0.13 | 0.14 | 0.14 | |
| Intangibles to total assets | 0 | 0 | 0 | 0 | 0 | |
| Capex to operating cash flow | -1.36 | 0.57 | 0.48 | 1.54 | -0.1 | |
| Capex to revenue | -0.06 | -0.04 | -0.03 | -0.11 | -0.04 | |
| Capex to depreciation | -2.9 | -2.59 | -2.08 | -6.84 | -2.26 | |
| Stock based compensation to revenue | 0.08 | 0.08 | 0.09 | 0.11 | 0 | |
| Graham number | 4.34 | 2.98 | 4.54 | 4.17 | 5.32 | |
| ROIC | 0 | 0 | 0.01 | 0.01 | 0.01 | |
| Return on tangible assets | 0.01 | 0.01 | 0.01 | 0.01 | 0.02 | |
| Graham Net | 3.9 | 3.84 | 3.9 | 4.01 | 4.28 | |
| Working capital | 260.26M | 265.81M | 273.81M | 290.29M | 300.23M | |
| Tangible asset value | 330.48M | 336.97M | 351.91M | 376.81M | 384.17M | |
| Net current asset value | 229.27M | 232.89M | 241.05M | 254.14M | 262.53M | |
| Invested capital | 0.09 | 0.09 | 0.09 | 0.09 | 0.09 | |
| Average receivables | 60.06M | 62.97M | 78.97M | 103.4M | 105.17M | |
| Average payables | 9.57M | 10.34M | 10.27M | 10.11M | 11.17M | |
| Average inventory | 22.05M | 25.98M | 26.65M | 28.27M | 33.1M | |
| Days sales outstanding | 87.76 | 77.72 | 92.08 | 125.93 | 115.61 | |
| Days payables outstanding | 73.07 | 51.31 | 47.72 | 47.43 | 78.48 | |
| Days of inventory on hand | 152.5 | 156.75 | 106.27 | 167.7 | 203.35 | |
| Receivables turnover | 1.03 | 1.16 | 0.98 | 0.71 | 0.78 | |
| Payables turnover | 1.23 | 1.75 | 1.89 | 1.9 | 1.15 | |
| Inventory turnover | 0.59 | 0.57 | 0.85 | 0.54 | 0.44 | |
| ROE | 0.02 | 0.01 | 0.02 | 0.01 | 0.02 | |
| Capex per share | -0.08 | -0.06 | -0.06 | -0.19 | -0.06 |
STAA Frequently Asked Questions
What is STAAR Surgical Company stock symbol ?
STAAR Surgical Company is a US stock , located in Lake forest of Ca and trading under the symbol STAA
What is STAAR Surgical Company stock quote today ?
STAAR Surgical Company stock price is $46.16 today.
Is STAAR Surgical Company stock public?
Yes, STAAR Surgical Company is a publicly traded company.
Company Profile
- Volume Average 736.24K
- Market Capitalization 2.43B
- Employee 1.06K
- CEO Mr. Thomas G. Frinzi
- Headquarters Lake Forest,CA,US
- IPO Date 1992-02-24
-
Website
https://www.staar.com 
STAAR Surgical Company, together with its subsidiaries, designs, develops, manufactures, markets, and sells implantable lenses for the eye, and companion delivery systems to deliver the lenses into the eye. The company provides Visian implantable Collamer lens product family (ICLs) to treat visual disorders, such as myopia, hyperopia, astigmatism, and presbyopia; and Hyperopic ICL, which treats far-sightedness. It also offers preloaded silicone cataract intraocular lenses and injector systems for use in cataract surgery. In addition, the company sells injector parts, and other related instruments and devices. It markets its products to health care providers, including ophthalmic surgeons, vision and surgical centers, hospitals, government facilities, and distributors, as well as products are primarily used by ophthalmologists. The company sells its products directly through its sales representatives in the United States, Japan, Germany, Spain, Canada, the United Kingdom, and Singapore, as well as through own representatives and independent distributors in China, Korea, India, France, Benelux, Italy, and internationally. STAAR Surgical Company was incorporated in 1982 and is headquartered in Lake Forest, California.
